Fibrogenesis in Crohn's Disease
暂无分享,去创建一个
N. Docherty | J. Burke | C. O'keane | R. Watson | J. Mulsow | P. O’Connell | John P Burke | Jurgen J Mulsow | Neil G. Docherty | R William G Watson | P. O'Connell | John P. Burke | R. Watson | P. O’Connell | P. R. O’Connell
[1] J. Fitzpatrick,et al. Expression and regulation of connective tissue growth factor by transforming growth factor β and tumour necrosis factor α in fibroblasts isolated from strictures in patients with Crohn's disease , 2006 .
[2] S. Hanauer,et al. Factors Associated with the Development of Intestinal Strictures or Obstructions in Patients with Crohn's Disease , 2006, The American Journal of Gastroenterology.
[3] L. Gesualdo,et al. CD40L proinflammatory and profibrotic effects on proximal tubular epithelial cells: role of NF-kappaB and lyn. , 2006, Journal of the American Society of Nephrology : JASN.
[4] P. Seksik,et al. Prior appendectomy and the phenotype and course of Crohn's disease. , 2006, World journal of gastroenterology.
[5] P. Rutgeerts,et al. Review article: infliximab therapy for inflammatory bowel disease – seven years on , 2006, Alimentary pharmacology & therapeutics.
[6] J. Mary,et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial , 2005, Gut.
[7] W. Hauswirth,et al. IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease. , 2005, Journal of the American Society of Nephrology : JASN.
[8] J. Gauldie,et al. Induction of a fibrogenic response in mouse colon by overexpression of monocyte chemoattractant protein 1 , 2005, Gut.
[9] H. Verspaget,et al. Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. , 2005, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[10] F. Galeazzi,et al. TGF-β1 gene transfer to the mouse colon leads to intestinal fibrosis , 2005 .
[11] P. Rutgeerts,et al. Safety and tolerability of antagonist anti‐human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease , 2005, Alimentary pharmacology & therapeutics.
[12] M. Yazdanbakhsh,et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. , 2005, The Journal of allergy and clinical immunology.
[13] P. Rutgeerts,et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. , 2005, Gastroenterology.
[14] R. Kalluri,et al. Bone Morphogenic Protein-7 Induces Mesenchymal to Epithelial Transition in Adult Renal Fibroblasts and Facilitates Regeneration of Injured Kidney* , 2005, Journal of Biological Chemistry.
[15] Michael Karin,et al. Nod2 Mutation in Crohn's Disease Potentiates NF-κB Activity and IL-1ß Processing , 2005, Science.
[16] L. Beaugerie,et al. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery , 2005, Gut.
[17] S. Gray,et al. Time and Dose Effects of Mitomycin C on Extracellular Matrix Fibroblasts and Proteins , 2005, The Laryngoscope.
[18] A. Senagore,et al. Does Conversion of a Laparoscopic Colectomy Adversely Affect Patient Outcome? , 2004, Diseases of the colon and rectum.
[19] M. Pines,et al. Prevention of Fibrosis in Experimental Colitis by Captopril: the Role of tgf-β1 , 2004, Inflammatory bowel diseases.
[20] R. Thisted,et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. , 2004, Gastroenterology.
[21] J. Fitzpatrick,et al. Critical involvement of stress-activated mitogen-activated protein kinases in the regulation of intracellular adhesion molecule-1 in serosal fibroblasts isolated from patients with Crohn's disease. , 2004, Journal of the American College of Surgeons.
[22] E. Fleck,et al. Regulation of matrix metalloproteinase MT1-MMP/MMP-2 in cardiac fibroblasts by TGF-beta1 involves furin-convertase. , 2004, Cardiovascular research.
[23] M. Goppelt‐Struebe,et al. Differential effects of simvastatin on mesangial cells. , 2004, Kidney international.
[24] P. Rutgeerts,et al. A randomized, double-blind, placebo-controlled trial of the human anti-TNF-α monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn’s disease , 2004 .
[25] E. Loftus. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. , 2004, Gastroenterology.
[26] Andrew Leask,et al. TGF‐β signaling and the fibrotic response , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[27] L. Eckmann. Innate immunity and mucosal bacterial interactions in the intestine , 2004, Current opinion in gastroenterology.
[28] J. Hugot. Genetic Origin of IBD , 2004, Inflammatory bowel diseases.
[29] P. Sime,et al. Expression of CD154 (CD40 Ligand) by Human Lung Fibroblasts: Differential Regulation by IFN-γ and IL-13, and Implications for Fibrosis1 , 2004, The Journal of Immunology.
[30] P. Rutgeerts,et al. Medical Therapy for Crohn's Disease Strictures , 2004, Inflammatory bowel diseases.
[31] J. Fitzpatrick,et al. Increased vascular endothelial growth factor production in fibroblasts isolated from strictures in patients with Crohn's disease , 2004, The British journal of surgery.
[32] J. Hugot,et al. Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. , 2003, Trends in immunology.
[33] J. Willis,et al. A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. , 2003, Gastroenterology.
[34] Judy H. Cho,et al. Defining Complex Contributions of NOD2/CARD15 Gene Mutations, Age at Onset, and Tobacco Use On Crohn's Disease Phenotypes , 2003, Inflammatory bowel diseases.
[35] Shokei Kim,et al. Regulation of IL-11 expression in intestinal myofibroblasts: role of c-Jun AP-1- and MAPK-dependent pathways. , 2003, American journal of physiology. Gastrointestinal and liver physiology.
[36] S. Vukicevic,et al. Bone morphogenetic protein‐7 reduces the severity of colon tissue damage and accelerates the healing of inflammatory bowel disease in rats , 2003, Journal of cellular physiology.
[37] Gary R. Grotendorst,et al. Connective tissue growth factor expression and action in human corneal fibroblast cultures and rat corneas after photorefractive keratectomy. , 2003, Investigative ophthalmology & visual science.
[38] D. Abraham,et al. Connective Tissue Growth Factor Gene Regulation , 2003, The Journal of Biological Chemistry.
[39] B. Saunders,et al. Long-Acting Steroid Injection after Endoscopic Dilation of Anastomotic Crohn’s Strictures May Improve the Outcome: A Retrospective Case Series , 2003, Endoscopy.
[40] J. Belaiche,et al. Early development of stricturing or penetrating pattern in Crohn’s disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype , 2003, Gut.
[41] M. Sans,et al. The 4G/4G genotype of the 4G/5G polymorphism of the type‐1 plasminogen activator inhibitor (PAI‐1) gene is a determinant of penetrating behaviour in patients with Crohn's disease , 2003, Alimentary pharmacology & therapeutics.
[42] S. Watson,et al. Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. , 2003, The American journal of pathology.
[43] P. Knaus,et al. Integration of the TGF-β pathway into the cellular signalling network , 2002 .
[44] H. Ihn. Pathogenesis of fibrosis: role of TGF-β and CTGF , 2002 .
[45] D. Abraham,et al. Prostacyclin derivatives prevent the fibrotic response to TGFβ2 by inhibiting the Ras/MEK/ERK pathway , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[46] T. Keku,et al. IGF-I and TGF-beta1 have distinct effects on phenotype and proliferation of intestinal fibroblasts. , 2002, American journal of physiology. Gastrointestinal and liver physiology.
[47] R. Goldschmeding,et al. Nitric oxide down-regulates connective tissue growth factor in rat mesangial cells. , 2002, Kidney international.
[48] F. Carbonnel,et al. Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.
[49] W. Rowe,et al. Remicade® Does Not Abolish the Need for Surgery in Fistulizing Crohn’s Disease , 2002, Diseases of the colon and rectum.
[50] M. Vatn,et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study , 2002, The Lancet.
[51] M. Ferrini,et al. Antifibrotic role of inducible nitric oxide synthase. , 2002, Nitric oxide : biology and chemistry.
[52] T. Ahmad,et al. The molecular classification of the clinical manifestations of Crohn's disease. , 2002, Gastroenterology.
[53] C. O'Morain,et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. , 2002, American journal of human genetics.
[54] J. Fitzpatrick,et al. Increased Adhesion Molecule Expression in Serosal Fibroblasts Isolated From Patients with Inflammatory Bowel Disease is Secondary to Inflammation , 2002, Annals of surgery.
[55] B. Tran,et al. Endothelin-1 stimulates human colonic myofibroblast contraction and migration , 2002, Gut.
[56] J. Belaiche,et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease , 2001, Gut.
[57] D. Abraham,et al. Transforming growth factor-&bgr; and connective tissue growth factor: key cytokines in scleroderma pathogenesis , 2001, Current opinion in rheumatology.
[58] T. Macdonald,et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. , 2001, The Journal of clinical investigation.
[59] M. Goppelt‐Struebe,et al. Rho‐dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins) , 2001, British journal of pharmacology.
[60] C. Godson,et al. Connective tissue growth factor: an attractive therapeutic target in fibrotic renal disease , 2001, Expert opinion on therapeutic targets.
[61] D. Abraham,et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. , 2001, The Journal of clinical investigation.
[62] Mourad Sahbatou,et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.
[63] D. Nicolae,et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease , 2001, Nature.
[64] E. Weiss,et al. Laparoscopic surgery for inflammatory bowel disease , 2001, Surgical Endoscopy.
[65] J. Church,et al. Safety and longterm efficacy of strictureplasty in 314 patients with obstructing small bowel Crohn's disease. , 2001, Journal of the American College of Surgeons.
[66] H. Freeman. Application of the Montreal classification for Crohn's disease to a single clinician database of 1015 patients. , 2001, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[67] F. Farrokhyar,et al. Low mortality in ulcerative colitis and Crohn's disease in three regional centers in England , 2001, American Journal of Gastroenterology.
[68] M. Keighley,et al. Wide-lumen stapled anastomosisvs. conventional end-to-end anastomosis in the treatment of Crohn's disease , 2001, Diseases of the colon and rectum.
[69] R. Sartor,et al. IGF-I and procollagen alpha1(I) are coexpressed in a subset of mesenchymal cells in active Crohn's disease. , 2000, American journal of physiology. Gastrointestinal and liver physiology.
[70] P. Rutgeerts,et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease , 2000 .
[71] J. Abraham,et al. CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. , 2000, Journal of molecular and cellular cardiology.
[72] J. Pucilowska,et al. Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. , 2000, American journal of physiology. Gastrointestinal and liver physiology.
[73] T. Macdonald,et al. Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease , 2000, Gut.
[74] S. Rosewicz,et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease , 2000, Gut.
[75] Toshiyuki Yamamoto,et al. Monocyte Chemoattractant Protein-1 Enhances Gene Expression and Synthesis of Matrix Metalloproteinase-1 in Human Fibroblasts by an Autocrine IL-1α Loop1 , 2000, The Journal of Immunology.
[76] J. Belaiche,et al. Increased production of matrix metalloproteinase‐3 and tissue inhibitor of metalloproteinase‐1 by inflamed mucosa in inflammatory bowel disease , 2000, Clinical and experimental immunology.
[77] Y. Yazaki,et al. Long-term outcome of non-surgical strictureplasty using metallic stents for intestinal strictures in Crohn's disease. , 2000, Gastrointestinal endoscopy.
[78] R. Cohen,et al. The cost of hospitalization in Crohn's disease , 2000, American Journal of Gastroenterology.
[79] D. Jewell,et al. A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 , 2000, Inflammatory bowel diseases.
[80] E. Bottinger,et al. A mechanism of suppression of TGF–β/SMAD signaling by NF-κB/RelA , 2000, Genes & Development.
[81] R. Tarnuzzer,et al. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in mesothelial cells and their regulation by transforming growth factor‐β1 , 1999, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.
[82] G. Camussi,et al. Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's disease , 1999, American Journal of Gastroenterology.
[83] Chun-xia Ma,et al. Regulation of matrix metalloproteinases (MMPs) and their tissue inhibitors in human myometrial smooth muscle cells by TGF-beta1. , 1999, Molecular human reproduction.
[84] P. Rutgeerts,et al. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. , 1999, Journal of immunology.
[85] A. Zinsmeister,et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. , 1999, Gastroenterology.
[86] J. Murray,et al. Laparoscopic colectomy: indications for conversion to laparotomy. , 1999, Archives of surgery.
[87] D. Jewell,et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. , 1999, Gastroenterology.
[88] P. Rubin,et al. Blockade of CD40-CD40 ligand interactions protects against radiation-induced pulmonary inflammation and fibrosis. , 1998, Clinical immunology and immunopathology.
[89] Gary R. Grotendorst,et al. Connective tissue growth factor: a novel regulator of mucosal repair and fibrosis in inflammatory bowel disease? , 1998, The international journal of biochemistry & cell biology.
[90] C. Billington,et al. Regulation of proliferation of human colonic subepithelial myofibroblasts by mediators important in intestinal inflammation. , 1998, The Journal of clinical investigation.
[91] Jean Weissenbach,et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16 , 1996, Nature.
[92] P. Munkholm,et al. Disease activity courses in a regional cohort of Crohn's disease patients. , 1995, Scandinavian journal of gastroenterology.
[93] P. Rutgeerts,et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. , 1995, Gastroenterology.
[94] J. Tjandra,et al. Long-term follow-up of strictureplasty in Crohn's disease , 1993, Diseases of the colon and rectum.
[95] Richard O. Hynes,et al. Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.
[96] H. Stein,et al. Cellular localization of procollagen gene transcripts in inflammatory bowel diseases. , 1992, Gastroenterology.
[97] M. Lark,et al. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression. , 1990, The Journal of biological chemistry.
[98] P. Rutgeerts,et al. Predictability of the postoperative course of Crohn's disease. , 1990, Gastroenterology.
[99] W. Schürch,et al. Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. , 1990, Laboratory investigation; a journal of technical methods and pathology.
[100] E. O'Keefe. Growth Factors and Other Aspects of Wound Healing: Biological and Clinical Implications , 1989 .
[101] D. Sachar,et al. Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. , 1988, Gut.
[102] R. Diegelmann,et al. Collagen content and types in the intestinal strictures of Crohn's disease. , 1988, Gastroenterology.
[103] R. Conigliaro,et al. Endoscopic dilation of anastomotic colonic stenosis by different techniques: an alternative to surgery? , 1987, Gastrointestinal endoscopy.
[104] S. Galandiuk,et al. Strictureplasty in diffuse Crohn's jejunoileitis , 1985, Diseases of the colon and rectum.
[105] R. Farmer,et al. Recurrence after surgery in Crohn's disease. Relationship to location of disease (clinical pattern) and surgical indication. , 1985, Gastroenterology.
[106] P. Rutgeerts,et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. , 1984, Gut.
[107] H. Ehrlich,et al. The identification of αA and αB collagen chains in hypertrophic scar , 1981 .
[108] R. Farmer,et al. Indications for surgery in Crohn's disease: analysis of 500 cases. , 1976, Gastroenterology.
[109] A. Bailey,et al. Characterization of the collagen of human hypertrophic and normal scars. , 1975, Biochimica et biophysica acta.
[110] J. Fitzpatrick,et al. Expression and regulation of connective tissue growth factor by transforming growth factor beta and tumour necrosis factor alpha in fibroblasts isolated from strictures in patients with Crohn's disease. , 2006, The British journal of surgery.
[111] J. Fitzpatrick,et al. Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling. , 2005, Annals of surgery.
[112] C. Jobin,et al. Tumor Necrosis Factor (TNF) (cid:1) Increases Collagen Accumulation and Proliferation in Intestinal Myofibroblasts via TNF Receptor 2 * , 2005 .
[113] P. Tighe,et al. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. , 2002, American journal of physiology. Cell physiology.
[114] Gary R. Grotendorst,et al. Connective tissue growth factor is directly related to liver fibrosis. , 2002, Hepato-gastroenterology.
[115] H. Ihn. Pathogenesis of fibrosis: role of TGF-beta and CTGF. , 2002, Current opinion in rheumatology.
[116] S. Targan,et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. , 2002, Gastroenterology.
[117] C. Prantera,et al. INFLAMMATION AND INFLAMMATORY BOWEL DISEASE Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG , 2002 .
[118] P. Knaus,et al. Integration of the TGF-beta pathway into the cellular signalling network. , 2002, Cellular signalling.
[119] H. Freeman,et al. Application of the Vienna Classification for Crohn's disease to a single clinician database of 877 patients. , 2001, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[120] P. Rutgeerts,et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. , 2000, Gastroenterology.
[121] J. Fitzpatrick,et al. Stricture formation in Crohn's disease: the role of intestinal fibroblasts. , 2000, Annals of surgery.
[122] P. Majmudar,et al. Topical mitomycin-C for subepithelial fibrosis after refractive corneal surgery. , 2000, Ophthalmology.
[123] M. Bitzer,et al. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. , 2000, Genes & development.
[124] H. Friess,et al. Transforming growth factor-betas and their signaling receptors are coexpressed in Crohn's disease. , 1999, Annals of surgery.
[125] H. Friess,et al. Transforming Growth Factor-βs and Their Signaling Receptors Are Coexpressed in Crohn's Disease , 1999 .
[126] D. Schuppan,et al. Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease. , 1992, Gastroenterology.
[127] C. Herfarth,et al. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. , 1989, Digestion.
[128] H. Ehrlich. The role of connective tissue matrix in wound healing. , 1988, Progress in clinical and biological research.
[129] Ehrlich Hp. The role of connective tissue matrix in wound healing. , 1988 .
[130] H. Ehrlich,et al. The identification of alpha A and alpha B collagen chains in hypertrophic scar. , 1981, Experimental and molecular pathology.
[131] O. Bonnevie,et al. The Long-term Prophylactic Effect of Salazosulfapyridine (SalazopyrinR) in Primarily Resected Patients with Crohn's Disease , 1978 .
[132] L. Bergman,et al. Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease. , 1976, Scandinavian journal of gastroenterology.
[133] I. Leodolter. [Crohn's disease]. , 1967, Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete.